Hexamethylmelamine (NSC-13875) alone and in combination with 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of advanced cancer.
D000284:Administration, Oral; D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002629:Chemosterilants / Q000009:adverse effects / Q000627:therapeutic use; D004123:Dimethylamines / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D009461:Neurologic Manifestations; D013921:Thrombocytopenia / Q000139:chemically induced; D014226:Triazenes / Q000009:adverse effects / Q000627:therapeutic use*; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
D000577:Amides; D000970:Antineoplastic Agents; D002629:Chemosterilants; D004123:Dimethylamines; D007093:Imidazoles; D014226:Triazenes; D014227:Triazines